Navigation Links
Response Genetics Announces Presentation/Webcast at BIOCOM Investor Conference
Date:10/31/2007

LOS ANGELES, Oct. 31 /PRNewswire-FirstCall/ -- Response Genetics, Inc. (Nasdaq: RGDX) today announced its President and CEO, Kathleen Danenberg, will provide a business overview, including an update on its ERCC-1 molecular diagnostic gene expression test for cisplatin-based chemotherapy resistance, at the BIOCOM Investor Conference at the San Diego Marriot Del Mar in San Diego October 31 to November 2. Ms. Danenberg will present at 5:30 p.m. PT Thursday, Nov. 1.

The presentation will be made available by webcast and can be accessed on the Media page of Response Genetics' website at http://www.responsegenetics.com.

About Response Genetics, Inc.

Response Genetics, Inc. ("RGI") (Nasdaq: RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of Response Genetics, Inc. (the "Company") related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties.

Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, its ERCC1 molecular diagnostic gene expression test for cisplatin-based chemotherapy resistance, and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward- looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward- looking statements, whether because of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE Response Genetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Stress response increases suicide risk
2. Gene variation simulates cholesterol response to oestrogen
3. Alcohol injures stress hormone response
4. Self control makes stress response easy
5. Perceived stress decreases vaccine response
6. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
7. Harmful chemicals change the genetic response to hormone estrogen
8. Increasing Insulin Response In Type 2 Diabetics With New Protein Mixture
9. Sexes differ in response to burnout on the job and depression
10. Reflecting On Personal Values Can Lower Stress Responses
11. Chromosome Ends Trigger DNA Damage Response For Telomere Protection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ... (LAIs), today announced a development collaboration with the Australian critical medicine company, ... such as schizophrenia. , LAI medicines can offer improved therapeutic benefits over oral ...
(Date:5/5/2016)... ... ... Einstein Medical is proud to announce that it has created ... at the 2016 ASCRS/ASOA Symposium and Congress, which takes place in New Orleans, LA ... Surgery and the American Society of Ophthalmic Administrations will be held at the Ernest ...
(Date:5/5/2016)... ... ... from Friday, May 6 - Sunday, May 8, fifteen elite athletes from Team Semper ... Mountain Bike Camp, hosted in conjunction with WTB and Cannondale in ... who’ll share pro tips with the injured veterans as they rip down some of the ...
(Date:5/5/2016)... Francisco, CA (PRWEB) , ... ... ... intensive lectures and hands-on exercises, the Wharton Seminars for Business Journalists ... a better understanding of key business and economic issues.  This one-day program ...
(Date:5/5/2016)... ... ... Derrin Doty Group has unveiled the latest charity campaign in their ongoing community ... The insurance provider’s caring team has been so moved by the sudden death of ... the flu, that they have decided to extend their original campaign. Compassionate community members ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 4, 2016 ... 154 pages, profiling 09 key companies and supported ... professional and in-depth study on the current state ... overview of the industry including definitions, classifications, applications ... analysis is provided for the international market including ...
(Date:5/3/2016)... Germany , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further ...    Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
Breaking Medicine Technology: